Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

ZARRILLI STEPHEN T

Huller Kelly

Norwalk Leslie V

Kline Kyle

Davidar David D

Thermo Fisher Scientific unveiled the EMPAD G2 detector, enabling faster 4D STEM materials analysis at 10,000 frames per second with atomic-scale characterization. The detector integrates with Velox software for simplified analysis. The global 4D STEM market is projected to grow from $68 million in 2024 to $110 million by 2031 at a 6.6% CAGR, supporting TMO's growth prospects in analytical instruments.

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

Neogen Corporation (NEOG) has demonstrated strong performance with shares rising 102.8% over the past year, outperforming the industry. The company's Food Safety division achieved its highest quarterly core growth rate since fiscal 2023 at 5.8%, while planning a 50% increase in fiscal 2027 R&D spending focused on innovation and pathogen detection. However, the company faces headwinds from foreign currency exposure affecting 51.2% of revenues and intense competition from larger corporations.

Neogen Surges 102.8% in a Year: What's Driving the Rally?

Illumina (ILMN) raised its 2026 revenue and EPS guidance following a 9.5% year-over-year revenue increase in Q2, driven by strong oncology clinical growth and expanded multiomics offerings. However, the company faces margin pressure from tariffs, freight costs, and memory inflation, with adjusted gross margin declining 120 basis points year-over-year despite manageable leverage and sufficient liquidity.

Should You Add Illumina Stock to Your Portfolio Now?

Teleflex (TFX), a Zacks Rank #2 (Buy) stock, benefits from strong growth in its Vascular business driven by central access demand, hemostatic products, and FDA approval of EZPLAZ. The Interventional platform is expanding through the BIOTRONIK acquisition with promising clinical development of Freesolve. However, foreign exchange sensitivity remains a key concern. The company has improved balance sheet flexibility with net leverage declining to 1.9X following strategic divestitures.

Globus Medical (GMED) Stock Price, Analysis & Trade Signals